Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 4 February 2020 – On 5 November 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.
Under the programme, initiated 5 November 2019, Novo Nordisk has repurchased B shares for an amount up to DKK 2.1 billion in the period from 6 November 2019 to 3 February 2020. The programme is now concluded.
Since the announcement as of 27 January 2020, the following transactions have been made:
|Accumulated, last announcement||4,832,350||1,878,714,254|
|27 January 2020||90,000||409.39||36,844,685|
|28 January 2020||90,000||406.33||36,570,124|
|29 January 2020||90,000||413.00||37,170,423|
|30 January 2020||90,000||413.32||37,198,355|
|31 January 2020||97,000||414.85||40,240,402|
|3 February 2020||96,232||411.39||39,588,765|
|Accumulated under the programme||5,385,582||2,106,327,008|
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 50,320,781 B shares of DKK 0.20, corresponding to 2.1% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 3 February 2020, Novo Nordisk has since 1 February 2019 repurchased a total of 43,209,505 B shares at an average share price of DKK 347.15 per B share equal to a transaction value of DKK 14,999,999,626.
|Anne Margrethe Hauge||+45 4442 email@example.com|
|Ken Inchausti (US)||+1 609 240 firstname.lastname@example.org|
|Peter Hugreffe Ankersen||+45 3075 email@example.com|
|Valdemar Borum Svarrer||+45 3079 firstname.lastname@example.org|
|Ann Søndermølle Rendbæk||+45 3075 email@example.com|
|Mark Joseph Root||+45 3079 firstname.lastname@example.org|
|Kristoffer Due Berg (US)||+1 609 235 email@example.com|
Company announcement No 6 / 2020
Upcoming Life Sciences Events
- February 2020
- Allschwil: Fundraising Bootcamp
- Amsterdam: Pharma & Biotech Patent Litigation
- March 2020
- : Evolution Summit